Neurocrine falls as investors question schizophrenia drug's trial data
** Shares of drugmaker Neurocrine Biosciences NBIX.O fall 15.5% to $128.9 premarket
** Co says during a mid-stage trial, the lowest 20-milligram dose of its schizophrenia drug NBI-1117568 achieved a 7.5 points reduction in a scale used to measure the severity of symptoms, compared with a placebo
** The lowest dose outperformed higher doses of the drug - a result that prompted investor questions over whether or not the data could be reproduced in larger trials
** The outperformance was "not something that is necessarily typical in this class - and something that is likely to call into question the replicability of the results in phase III (trials)," said RBC Capital analyst Brian Abrahams
** Several analysts also compared the trial results to Bristol Myers Squibb's BMY.N schizophrenia drug KarXT
** "Results underperform previous 11.6 point reduction seen by KarXT" - BMO Capital Markets
** Up to last close, NBIX stock up 15.8% YTD
Reporting by Christy Santhosh
Latest News
Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.
All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.
Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.
